Danaher Corporation
DHR
$218.49
+1.34%
Danaher Corporation is a global life sciences and diagnostics company that designs and manufactures scientific instruments, consumables, and diagnostic solutions used across biopharmaceutical research, clinical testing, and industrial applications. Following the late-2023 spin-off of its environmental and applied solutions unit, Veralto, Danaher has sharpened its identity as a pure-play healthcare technology platform, competing with the likes of Thermo Fisher Scientific, Agilent, and Sartorius in the high-margin tools and diagnostics arena. The current investor narrative centers on the durability of its post-COVID bioprocessing recovery, the earnings accretion from the recently closed Masimo acquisition, and whether the company can return to mid-single-digit organic growth after several quarters of uneven demand. Recent headlines have oscillated between optimism over M&A appetite in life sciences and concern over temporary shipment delays in the biotech segment, which triggered a sharp but short-lived selloff that some commentators have framed as a buying opportunity.…
DHR
Danaher Corporation
$218.49
Related headlines
Investment Opinion: Should I buy DHR Today?
The synthesized recommendation is a Hold. Danaher is a high-quality life sciences franchise with strong recurring revenue and cash flow, but the current valuation already reflects a significant earnings recovery, and the stock has lagged the market. The analyst consensus of 'strong_buy' with an average target of $234.73 implies only 9.7% upside, suggesting limited near-term appreciation potential.
The supporting evidence includes: 1) Forward PE of 23.01x is reasonable if EPS doubles to $12.48, but trailing PE of 45.15x is rich; 2) Revenue growth of 5.54% year-over-year is modest; 3) Net margin of 13.89% in Q2 2026 is below the 2025 full-year level of 17.51%; 4) Free cash flow of $5.466 billion TTM is robust; and 5) The implied upside to the average analyst target is 9.7%, which is not compelling for a stock with execution risks.
The biggest risks that could invalidate the thesis are a slower-than-expected bioprocessing recovery, margin pressure from the Masimo integration, and a premium valuation that could compress. The rating would upgrade to Buy if the stock pulls back to the $180-$190 range (forward PE ~15x) or if organic growth accelerates above 7%. It would downgrade to Sell if revenue growth falls below 3% or if margins continue to deteriorate. Relative to its history, the forward PE is attractive, but on a trailing basis, the stock is overvalued compared to peers and its own historical average.
Sign up to view all
DHR 12-Month Price Forecast
Danaher presents a balanced risk/reward profile. The company's high-quality recurring revenue and strong free cash flow are offset by sluggish growth and a premium valuation that already prices in a recovery. The forward PE of 23x is attractive if earnings double as expected, but the trailing PE of 45x leaves little margin for error. Analyst sentiment is bullish, but the modest upside to the average target suggests limited near-term catalysts. I would upgrade to bullish if bioprocessing demand shows clear acceleration and margins stabilize, and downgrade to bearish if organic growth decelerates below 3% or integration issues arise.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Danaher Corporation's 12-month outlook, with a consensus price target around $239.05 and implied upside of +9.4% versus the current price.
Average Target
$239.05
0 analysts
Implied Upside
+9.4%
vs. current price
Analyst Count
—
covering this stock
Price Range
$200 - $310
Analyst target range
Danaher is covered by 22 analysts, and the consensus is decidedly bullish, with a recommendation mean of 1.44 (where 1.0 is a Strong Buy and 2.0 is a Buy) and an overall rating of "strong_buy." The average price target is $234.73, which implies approximately 9.7% upside from the current price of $214.06. The distribution of recent institutional ratings skews heavily positive, with Buy or Outperform ratings from Stifel, RBC Capital, Guggenheim, TD Cowen, Evercore ISI, HSBC, and Morgan Stanley, while Wells Fargo, Piper Sandler, and Citigroup maintain more cautious Neutral or Equal Weight stances. The consensus leans clearly bullish, but the relatively modest implied upside suggests that much of the recovery story is already reflected in the current price. The target price range is wide, spanning from a low of $200.00 to a high of $310.00, a spread of $110 that signals meaningful disagreement about the company's trajectory. The high target of $310.00 implies roughly 45% upside and likely assumes a robust bioprocessing recovery, successful Masimo integration, multiple expansion back toward historical peaks, and accelerating organic growth. The low target of $200.00, which is about 6.6% below the current price, likely prices in continued demand headwinds, margin compression from acquisition amortization, and a slower-than-expected earnings recovery. The wide spread reflects genuine uncertainty about the timing and magnitude of the life sciences recovery, and the fact that several analysts have recently maintained rather than raised their ratings suggests the bullish case is well understood but not yet compelling enough to drive aggressive upward estimate revisions. With 22 analysts covering the stock and a strong buy consensus, coverage is robust and institutional interest is high, which supports efficient price discovery and limits the risk of extreme mispricing.
Bulls vs Bears: DHR Investment Factors
The bull case rests on Danaher's high-quality recurring revenue, strong free cash flow, and a clear forward earnings recovery that makes the stock appear reasonably valued on a forward basis. The bear case highlights sluggish organic growth, recent margin compression, and a premium valuation that leaves little room for disappointment. Currently, the bear evidence is slightly stronger given the stock's underperformance versus the market and the fact that the recovery is already priced in. The most critical tension is whether bioprocessing demand will inflect enough to drive the expected doubling of earnings; if it does, the stock could re-rate higher, but if it stalls, the downside could be significant.
Bullish
- Recurring revenue provides stability: Of the $6.265 billion in Q2 2026 revenue, $5.20 billion (83%) came from recurring sources, creating a predictable earnings base. This razor-and-blade model locks in consumables demand and supports Danaher's premium valuation.
- Forward earnings recovery priced in: The forward PE of 23.01x is less than half the trailing PE of 45.15x, implying the market expects EPS to roughly double to $12.48. This recovery is underpinned by bioprocessing normalization and the Masimo acquisition.
- Strong free cash flow generation: Trailing-twelve-month free cash flow is $5.466 billion, with Q2 2026 FCF of $1.265 billion from $1.534 billion operating cash flow. This self-funding capacity supports M&A and debt reduction without straining the balance sheet.
- Conservative balance sheet with low leverage: Debt-to-equity is just 0.351 and the current ratio is 1.874, indicating ample liquidity. The company repaid $8.485 billion in debt in Q2 2026, demonstrating financial flexibility.
Bearish
- Sluggish organic growth: Q2 2026 revenue grew only 5.54% year-over-year to $6.265 billion, and the multi-quarter trend shows lumpy demand. This pace is insufficient to justify a 6.59x PS ratio without margin expansion.
- Margin compression from acquisitions: Gross margin fell from 60.34% in Q1 2026 to 57.64% in Q2 2026, and net margin dropped from 17.29% to 13.89%. Acquisition-related costs and mix shifts are eroding profitability.
- Rich valuation on trailing metrics: The trailing PE of 45.15x and EV/EBITDA of 25.30x are elevated, leaving little room for error. The PEG ratio of -9.26 reflects negative trailing earnings growth, making the valuation entirely dependent on forward estimates.
- Technical resistance at 52-week high: The stock is at $214.06, about 12% below its 52-week high of $242.80, which serves as strong resistance. A failure to break through could lead to a retest of support at $160.93.
DHR Technical Analysis
Danaher is in a broad recovery phase rather than a sustained uptrend, with the stock up just 1.77% over the trailing year and still down 7.09% year-to-date, a notable laggard against the S&P 500's 15.01% one-year gain. At a current price of $214.06, the shares sit at roughly 88% of the 52-week range (low of $160.93, high of $242.80), meaning they have clawed back most of the drawdown from the highs but have not yet reclaimed them. This positioning suggests improving momentum without the overextension that typically accompanies a stock at fresh highs, though the negative 1-year relative strength of -13.24% versus SPY underscores that the recovery is still incomplete. Recent momentum is clearly positive and accelerating: the stock is up 1.98% over the past month, 8.15% over three months, and 12.00% over six months, with the 3-month relative strength of +4.81% against SPY confirming genuine outperformance in the intermediate term. The 1-month gain of 1.98% versus SPY's 0.59% yields a relative strength of +1.39%, showing the stock is participating in the market's advance but not dramatically outpacing it. The divergence between the strong 3-month and 6-month trends and the flat 1-year performance implies the stock spent the first half of the year absorbing a sharp drawdown — the max drawdown of -33.11% — before establishing a higher base, a pattern consistent with a bottoming-and-recovery structure rather than a fresh breakout. Key technical levels are well defined: the 52-week low at $160.93 represents the critical support zone that held during the spring selloff, while the 52-week high at $242.80 is the primary resistance level that must be cleared to confirm a new uptrend. A breakout above $242.80 would signal that the market is pricing in a full earnings recovery and could open the door to a retest of prior highs, whereas a breakdown below $160.93 would invalidate the recovery thesis and suggest the downtrend is resuming. With a beta of 0.808, Danaher is roughly 19% less volatile than the broader market, which means position sizing can be somewhat larger for a given risk budget, but the stock's defensive characteristics also imply it may lag in strong risk-on rallies — a dynamic already visible in its underperformance versus SPY over the past year.
Beta
0.80
0.80x market volatility
Max Drawdown
-33.1%
Largest decline past year
52-Week Range
$161-$243
Price range past year
Annual Return
+4.7%
Cumulative gain past year
| Period | DHR Return | S&P 500 |
|---|---|---|
| 1m | +5.2% | +0.9% |
| 3m | +11.5% | +3.4% |
| 6m | +15.2% | +14.4% |
| 1y | +4.7% | +16.2% |
| ytd | -5.2% | +14.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
DHR Fundamental Analysis
Danaher's revenue trajectory is modestly positive but not yet inspiring, with Q2 2026 revenue of $6.265 billion representing 5.54% year-over-year growth from the $5.936 billion reported in Q2 2025. The multi-quarter trend shows a company grinding through a slow recovery: revenue rose from $5.741 billion in Q1 2025 to $6.053 billion in Q3 2025, dipped to $5.951 billion in Q1 2026, and then recovered to $6.265 billion in Q2 2026, a pattern that suggests lumpy demand rather than a smooth acceleration. The revenue mix is heavily weighted toward recurring revenue, with $5.20 billion of the $6.265 billion total coming from recurring sources versus $1.065 billion from nonrecurring, a structure that provides earnings stability but also means growth is tethered to consumables pull-through rather than large equipment placements. The investment case hinges on whether bioprocessing demand inflects higher as biopharma R&D budgets normalize, and the recent Masimo acquisition adds a new diagnostic monitoring revenue stream that could supplement organic growth. Profitability remains a core strength: Q2 2026 net income was $870 million on a 13.89% net margin, with gross margin at 57.64% and operating margin at 17.99%, though these figures are below the company's historical peaks. The gross margin trend has been uneven, falling from 60.34% in Q1 2026 to 57.64% in Q2 2026, and net margin compressed from 17.29% to 13.89% over the same period, partly reflecting acquisition-related costs and mix shifts. Compared to the 2025 full-year net margin of 17.51% and gross margin of 58.00%, the current quarter represents a modest deterioration, but the company remains solidly profitable and generates returns that are respectable for the life sciences tools industry, where high margins are the norm. The balance sheet is conservatively managed, with a debt-to-equity ratio of 0.351 and a current ratio of 1.874, indicating ample liquidity and modest leverage. Free cash flow on a trailing-twelve-month basis is $5.466 billion, and the Q2 2026 free cash flow of $1.265 billion was supported by $1.534 billion in operating cash flow against $269 million in capital expenditures. However, the company deployed $9.843 billion on acquisitions in Q2 2026 and repaid $8.485 billion in debt, funded partly by $7.273 billion in net financing inflows, which explains the $1.353 billion net cash decrease for the quarter. ROE of 6.88% and ROA of 3.95% are modest relative to the company's historical norms, reflecting the dilutive effect of recent M&A and the amortization burden, but the strong FCF generation and low leverage suggest the company can fund its growth internally without undue financial risk.
Quarterly Revenue
$6.3B
2026-06
Revenue YoY Growth
+5.5%
YoY Comparison
Gross Margin
57.6%
Latest Quarter
Free Cash Flow
$5.5B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is DHR Overvalued?
Because Danaher is solidly profitable with positive net income of $870 million in the most recent quarter, the PE ratio is the appropriate primary valuation metric. The trailing PE stands at 45.15x, while the forward PE is 23.01x, a dramatic gap that implies the market expects earnings to roughly double over the next twelve months — a forecast supported by the analyst consensus EPS estimate of $12.48 versus the trailing EPS of approximately $4.74 implied by the trailing PE. This wide spread between trailing and forward multiples signals that the market is pricing in a substantial earnings recovery, likely driven by the normalization of bioprocessing demand, the full contribution of the Masimo acquisition, and operating leverage as volumes recover. On a peer comparison basis, the forward PE of 23.01x is difficult to assess without a direct industry average from the provided data, but the PS ratio of 6.59x and EV/Sales of 6.87x are informative: for a company growing revenue at 5.54% with a 14.71% net margin, a 6.6x sales multiple represents a premium that the market is willing to pay for Danaher's recurring revenue base and franchise quality. The EV/EBITDA of 25.30x is elevated relative to the broader market but consistent with high-quality life sciences tools companies that command premium multiples for their razor-and-blade business models and strong free cash flow conversion. The PEG ratio of -9.26 is not meaningful given the negative earnings growth implied by trailing figures, which underscores that the valuation is entirely dependent on the forward earnings recovery materializing. Historically, Danaher's PE ratio has ranged from a low of around 19.4x in Q4 2022 to a high of 64.5x in Q2 2025, with the current trailing PE of 45.15x sitting in the upper-middle portion of that range. The PS ratio of 6.59x is near the low end of its historical band, which has ranged from roughly 21.4x to 34.3x over the past several years — though this comparison is distorted by the Veralto spin-off, which reduced the revenue base and mechanically inflated historical PS ratios. More relevant is the forward PE of 23.01x, which is below the trailing PE at most points in the historical data and suggests that if earnings recover as expected, the stock is not expensive on a normalized basis. The key risk is that the market is pricing in an optimistic recovery that could be delayed by persistent bioprocessing headwinds or integration challenges from the Masimo deal.
PE
45.2x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 19x~51x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
25.3x
Enterprise Value Multiple
Investment Risk Disclosure
Danaher's financial risks are moderate but notable. The debt-to-equity ratio of 0.351 is conservative, but the company deployed $9.843 billion on acquisitions in Q2 2026, funded partly by $7.273 billion in net financing inflows, which led to a $1.353 billion net cash decrease. Margin pressure is evident: gross margin fell from 60.34% in Q1 2026 to 57.64% in Q2 2026, and net margin compressed from 17.29% to 13.89%, partly due to acquisition amortization. Additionally, revenue growth of 5.54% year-over-year is modest, and the business remains heavily dependent on bioprocessing demand, which has been uneven.
Market and competitive risks are significant. The stock trades at a premium valuation with a trailing PE of 45.15x and EV/EBITDA of 25.30x, leaving it vulnerable to multiple compression if growth disappoints. Competition from Thermo Fisher, Agilent, and Sartorius is intense, and Danaher's beta of 0.808 indicates it is less volatile than the market but may lag in strong rallies. Recent news highlights temporary shipment delays in the biotech segment that caused a 12% weekly drop in July 2026, underscoring sensitivity to operational hiccups. The Masimo acquisition, while strategic, carries integration risk and has raised questions about the deal's valuation.
The worst-case scenario would involve a prolonged delay in bioprocessing recovery, integration missteps with Masimo, and further margin erosion. In such a scenario, the stock could retest its 52-week low of $160.93, representing a 24.8% decline from the current price of $214.06. The analyst low target of $200.00 implies a 6.6% downside, but a more severe selloff could occur if forward earnings estimates are revised downward. Given the max drawdown of -33.11% over the past year, investors could face losses exceeding 30% in a bear case.
FAQ
The key risks include: 1) Financial risks: margin compression, with net margin falling to 13.89% in Q2 2026 from 17.51% in 2025, and high trailing valuation. 2) Competitive risks: intense competition from Thermo Fisher and others, and potential market share loss. 3) Macro risks: beta of 0.808 means less volatility but also underperformance in strong markets, and sensitivity to biopharma R&D spending. 4) Company-specific risks: integration challenges from the Masimo acquisition and execution risk in bioprocessing recovery. The most severe risk is a prolonged delay in bioprocessing demand, which could lead to a 25% downside to the 52-week low.
The 12-month forecast has three scenarios: bull case (25% probability) with a target range of $260-$310, base case (55% probability) with a target range of $220-$250, and bear case (20% probability) with a target range of $160-$200. The base case is most likely, assuming gradual recovery and mid-single-digit growth, aligning with the analyst average target of $234.73. The key assumption is that bioprocessing demand normalizes and margins stabilize. A breakout above $242.80 would confirm the bull case, while a breakdown below $160.93 would signal the bear case.
DHR appears fairly valued on a forward basis but overvalued on trailing metrics. The forward PE of 23.01x is reasonable if earnings double to $12.48 as expected, but the trailing PE of 45.15x and EV/EBITDA of 25.30x are elevated. The PS ratio of 6.59x is a premium for a company growing revenue at 5.54%. Compared to its own history, the forward PE is below the trailing average, suggesting the market expects a recovery. However, the stock is not cheap relative to peers, and the valuation implies the market is pricing in a successful turnaround.
DHR is a good buy for long-term investors who believe in the bioprocessing recovery and are willing to accept a premium valuation. The stock trades at $214.06, with a forward PE of 23.01x and an average analyst target of $234.73, implying 9.7% upside. However, the trailing PE of 45.15x and recent margin compression suggest limited margin of safety. The biggest downside risk is a retest of the 52-week low at $160.93, representing 24.8% downside. For risk-averse investors, waiting for a pullback or clearer growth signals may be prudent.
DHR is more suitable for long-term investment due to its defensive characteristics, recurring revenue, and dividend yield of 0.54%. The beta of 0.808 indicates lower volatility, making it less ideal for short-term trading. The stock has underperformed the market over the past year, but the forward earnings recovery could take time to materialize. A minimum holding period of 2-3 years is recommended to allow for the bioprocessing recovery and Masimo integration to play out. Short-term traders might find opportunities around earnings or technical levels, but the risk/reward is less favorable.